Who is sponsoring NCT06611579?

NCT06611579 is sponsored by inQB8 Medical Technologies, LLC.

What drugs are being tested in NCT06611579?

Interventions in NCT06611579: Transcatheter Tricuspid Valve Replacement.

What condition does NCT06611579 study?

NCT06611579 studies Tricuspid Valve Regurgitation.

Is NCT06611579 still recruiting?

NCT06611579 is currently recruiting now. Last updated 4 November 2025.

Last reviewed 2025-11-04 · How we verify

NCT06611579

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study of the inQB8 TTVR System

Recruiting now NA Last updated 4 November 2025

What this trial tests

NA trial testing Transcatheter Tricuspid Valve Replacement in Tricuspid Valve Regurgitation in 50 participants. Currently enrolling.

Timeline

1 June 2025

Primary endpoint
31 October 2026

31 October 2029

Quick facts

Lead sponsor	inQB8 Medical Technologies, LLC
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 June 2025
Primary completion	31 October 2026
Estimated completion	31 October 2029
Sites	6 locations across United States

Drugs / interventions tested

Transcatheter Tricuspid Valve Replacement

Conditions studied

Tricuspid Valve Regurgitation — all drugs for Tricuspid Valve Regurgitation →

Sponsor

inQB8 Medical Technologies, LLC

Who can join

18 and older, any sex, with Tricuspid Valve Regurgitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prospective, multi-center study to assess safety and performance of the inQB8 MonarQ Tricuspid Valve Replacement System.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Transcatheter Tricuspid Valve Replacement

Trials testing the same drug.

NCT06569602 — Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU) · recruiting
NCT06581471 — The TRICURE EU Pivotal Study · NA · recruiting
NCT04905017 — Trisol System EFS Study · NA · recruiting
NCT04221490 — 2019-06 TRISCEND Study · NA · active not recruiting

Other recruiting trials for Tricuspid Valve Regurgitation

Currently open trials in the same condition.

NCT07267117 — Cohort Observing Mechanisms, Progression and Sequelae of Valvular Heart Disease · recruiting
NCT06569602 — Real World European Investigation of Safety and Clinical Efficacy of the EVOQUE System (TRISCEND III EU) · recruiting
NCT06581471 — The TRICURE EU Pivotal Study · NA · recruiting
NCT07342036 — Prospective Study of Lead-associated Tricuspid Regurgitation in Patients Undergoing New Transvalvular Lead Insertion · recruiting
NCT05760989 — TRISCEND JAPAN Study · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06611579 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by inQB8 Medical Technologies, LLC
Last refreshed: 4 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06611579.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing